J&J to acquire Ollin Biosciences for $2.2 billion upfront
FROM THE WIRE · FINANCE.YAHOO.COM
Johnson & Johnson JNJ has been actively pursuing strategic acquisitions to strengthen its Innovative Medicine and MedTech businesses, diversify its portfolio and accelerate long-term revenue growth. The company has been increasingly focused on acquiring promising drug…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: neutralAcquisition of a clinical-stage biotech that expands a large pharma company's ophthalmology pipeline.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01J&J announced a definitive agreement to acquire Ollin Biosciences.
- 02The upfront payment is $2.2 billion, with milestones of about $1.125 billion.
- 03The asset OLN324 is a phase III bispecific antibody for retinal diseases.
NEWS IMPACT AND MARKET REACTIONChange from the reference price
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets